Next-generation cancer vaccine approaches: Integrating lessons learned from current successes with promising biotechnologic advances

Research output: Contribution to journalArticle

Abstract

With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.

Original languageEnglish (US)
Pages (from-to)766-772
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number7
StatePublished - Jul 1 2013

Fingerprint

Cancer Vaccines
Neoplasms
Tumor Microenvironment
Castration
Biotechnology
Immunotherapy
Melanoma
Prostatic Neoplasms
Vaccines
Clinical Trials
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

@article{c85195bbbdd748a09bd0fac99b0c665d,
title = "Next-generation cancer vaccine approaches: Integrating lessons learned from current successes with promising biotechnologic advances",
abstract = "With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.",
author = "Dung Le and Elizabeth Jaffee",
year = "2013",
month = "7",
day = "1",
language = "English (US)",
volume = "11",
pages = "766--772",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Next-generation cancer vaccine approaches

T2 - Integrating lessons learned from current successes with promising biotechnologic advances

AU - Le, Dung

AU - Jaffee, Elizabeth

PY - 2013/7/1

Y1 - 2013/7/1

N2 - With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.

AB - With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84882984973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882984973&partnerID=8YFLogxK

M3 - Article

C2 - 23847215

AN - SCOPUS:84882984973

VL - 11

SP - 766

EP - 772

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 7

ER -